NS
Article DetailSEC EDGAR Filings
SEC EDGAR Filings

8-K - 8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) () - 1.01 / 2.03 / 3.02 / 9.01

Filed: 2026-04-14 AccNo: 0001213900-26-043519 Size: 257 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
发布时间04/14 20:01 UTC
首次发现04/14 20:04 UTC
热度106.7
重要度78
情绪-0.04

站内整理正文

优先显示结构化正文;如果正文还未抽出,则回退到摘要。
sec_edgar_index_v1 · 982 字符

Form 8-K - Current report: SEC Accession No. 0001213900-26-043519

Filing Date: 2026-04-14

Accepted: 2026-04-14 16:01:08

Documents: 12

Period of Report: 2026-04-08

Items: Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK : 0001870404 (see all company filings) EIN. : 871088814 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 26860816 SIC : 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)

1 | CURRENT REPORT | ea0286319-8k_cero.htm iXBRL | 8-K

2 | XBRL SCHEMA FILE | cero-20260408.xsd | EX-101.SCH

3 | XBRL DEFINITION FILE | cero-20260408_def.xml | EX-101.DEF

4 | XBRL LABEL FILE | cero-20260408_lab.xml | EX-101.LAB